NYSE: AIM - AIM ImmunoTech Inc.

Rentabilidad a seis meses: -50.01%
Rendimiento de dividendos: 0.00%
Sector: Healthcare

Calendario de promoción AIM ImmunoTech Inc.

Horario avanzado gráfico sencillo
Financial Markets by TradingView

Acerca de la empresa AIM ImmunoTech Inc.

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).

más detalles
It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Añadir a la lista de comparación
Añadir a la lista de vigilancia
Añadir al portafolio
Añadir aviso de precio

IPO date 1996-07-12
ISIN US00901B1052
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://aimimmuno.com
Цена ао 0.2969
Cambio de precio por día: -3.92% (0.255)
Cambio de precio por semana.: +0.823% (0.243)
Cambio de precio por mes: -29.6% (0.348)
Cambio de precio en 3 meses.: -32.02% (0.3604)
Cambio de precio en seis meses: -50.01% (0.4901)
Cambio de precio por año: -57.02% (0.57)
Cambio de precio en 3 años.: -87.63% (1.98)
Cambio de precio en 5 años.: -90.65% (2.62)
Cambio de precio en 10 años.: 0% (0.245)
Cambio de precio desde principios de año.: -30.99% (0.355)
Todos los parámetros

Subestimación

Nombre Significado Calificación
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Total: 2.5

Eficiencia

Nombre Significado Calificación
ROA, % 0 0
ROE, % 0 0
Total: 0

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0 0
Total: 0

Deber

Nombre Significado Calificación
Debt/EBITDA 0 10
Total: 10

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % -61.58 0
Rentabilidad Ebitda, % 70.45 8
Rentabilidad EPS, % -92.56 0
Total: 5
Más detalles

Instituciones Volumen Compartir, %
Vanguard Group Inc 1988704 3.99
Blackrock Inc. 707806 1.42
Geode Capital Management, LLC 351657 0.7
Renaissance Technologies, LLC 202008 0.4
State Street Corporation 173103 0.35
Verition Fund Management, LLC 162000 0.32
Bridgeway Capital Management, Inc. 108900 0.22
Northern Trust Corporation 85566 0.17
Morgan Stanley 77318 0.15
Seacrest Wealth Management, LLC 37063 0.07

ETF Compartir, % Rentabilidad del año, % Dividendos, %
SPDR S&P International Small Cap ETF 0.02113 8.94 3.10348
Dimensional International Small Cap Value ETF 0.00214 7.13 4.55441
SPDR Portfolio Developed World ex-US ETF 0.00183 5.29 3.28401
Avantis Responsible International Equity ETF 0.00127 17.44 3.61591
Dimensional International Small Cap ETF 0.00079 5.69 3.34747
Avantis International Equity ETF 0.0002 6.46 3.80856



Supervisor Título profesional Pago año de nacimiento
Mr. Thomas K. Equels Esq., J.D., M.S. Executive Vice Chairman, CEO & President 953.19k 1953 (72 año)
Mr. Robert Dickey IV, M.B.A. Chief Financial Officer 64.48k 1956 (69 años)
Mr. Peter W. Rodino III, Esq., J.D. COO, Executive Director of Governmental Relations, General Counsel & Secretary 484.94k 1951 (74 año)
Ann Marie E. Coverly Director of Administration & Human Resources and Deputy Investor Relations Coordinator N/A
Dr. Christopher McAleer Ph.D. Scientific Officer N/A
Dr. Ralph Christopher Cavalli Ph.D. Vice President of QC & Manufacturing 234.79k 1958 (67 años)

DIRECCIÓN: United States, Ocala. FL, 2117 SW Highway 484 - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://aimimmuno.com